Veeva Systems Inc. $VEEV Shares Sold by Zevenbergen Capital Investments LLC

Zevenbergen Capital Investments LLC reduced its holdings in shares of Veeva Systems Inc. (NYSE:VEEV) by 3.3% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 198,275 shares of the technology company’s stock after selling 6,668 shares during the period. Veeva Systems accounts for about 1.1% of Zevenbergen Capital Investments LLC’s investment portfolio, making the stock its 27th biggest holding. Zevenbergen Capital Investments LLC’s holdings in Veeva Systems were worth $59,068,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in VEEV. ASR Vermogensbeheer N.V. increased its stake in shares of Veeva Systems by 64.2% during the second quarter. ASR Vermogensbeheer N.V. now owns 5,167 shares of the technology company’s stock worth $1,488,000 after buying an additional 2,020 shares during the period. Stevens Capital Management LP acquired a new position in Veeva Systems during the 2nd quarter worth approximately $306,000. QRG Capital Management Inc. grew its holdings in Veeva Systems by 15.7% during the 2nd quarter. QRG Capital Management Inc. now owns 12,771 shares of the technology company’s stock worth $3,678,000 after acquiring an additional 1,735 shares in the last quarter. Merit Financial Group LLC increased its position in shares of Veeva Systems by 12.5% in the 2nd quarter. Merit Financial Group LLC now owns 45,247 shares of the technology company’s stock valued at $13,030,000 after purchasing an additional 5,042 shares during the last quarter. Finally, FORA Capital LLC acquired a new stake in shares of Veeva Systems in the 2nd quarter valued at $4,420,000. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $355.00 price objective on shares of Veeva Systems in a research report on Friday, November 21st. Mizuho lifted their price target on Veeva Systems from $295.00 to $325.00 and gave the stock an “outperform” rating in a report on Friday, August 29th. TD Cowen upgraded Veeva Systems from a “hold” rating to a “buy” rating and increased their price objective for the company from $297.00 to $380.00 in a report on Tuesday, October 7th. Piper Sandler raised their target price on Veeva Systems from $325.00 to $355.00 and gave the stock an “overweight” rating in a research report on Thursday, August 28th. Finally, Canaccord Genuity Group restated a “buy” rating on shares of Veeva Systems in a research note on Tuesday, November 25th. Eighteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $307.42.

Insider Transactions at Veeva Systems

In other Veeva Systems news, insider Eleni Nitsa Zuppas sold 6,000 shares of the firm’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the completion of the transaction, the insider owned 25,325 shares of the company’s stock, valued at approximately $7,765,151.50. This trade represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Thomas D. Schwenger sold 3,350 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the completion of the transaction, the insider directly owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. This represents a 12.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 24,665 shares of company stock valued at $7,438,000 in the last ninety days. Corporate insiders own 10.30% of the company’s stock.

Veeva Systems Stock Performance

Shares of NYSE VEEV opened at $222.11 on Friday. Veeva Systems Inc. has a one year low of $201.54 and a one year high of $310.50. The company’s fifty day moving average is $265.47 and its two-hundred day moving average is $276.91. The firm has a market capitalization of $36.51 billion, a P/E ratio of 43.21, a PEG ratio of 1.62 and a beta of 1.05.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The company had revenue of $0.81 million for the quarter, compared to analyst estimates of $792.37 million. During the same period in the prior year, the business posted $1.75 earnings per share. The firm’s revenue for the quarter was up 16.0% compared to the same quarter last year. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. On average, sell-side analysts forecast that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Veeva Systems Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.